Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research. "ATTR is a progressive, fatal disease in which misfolded transthyretin protein accumulates as amyloid deposits in various parts of the body, often damaging the heart. HELIOS-B was a randomized, double-blind trial in patients with ATTR-CM (hereditary or wild-type) who had evidence of cardiac amyloidosis by echocardiography and confirmed ATTR amyloid deposition. Patients were randomized in a 1:1 ratio to vutrisiran 25 mg or placebo administered subcutaneously once every three months for up to 36 months. If the...